NYSE · ABT
Abbott Laboratories
$104.57+$1.93 (+1.88%)
Abbott Laboratories’s quoted price sits in the lower half of its reported 52-week range, 20.8% below the high.
Loading market information…
NYSE · PEN · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Penumbra, Inc.’s quoted price sits in the upper half of its reported 52-week range, 11.16% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Penumbra, Inc.’s next earnings report is currently expected on Nov 4, 2026, with estimated earnings per share of $1.20. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Penumbra, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:09 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 |
|---|
| Apr 23, 2025 |
| $0.83+25.76% vs estimate |
| $324.14M-0.96% vs estimate |
| Q4 2024 | Feb 18, 2025 | $0.97+10.23% vs estimate | $315.52M+1.25% vs estimate |
|---|
| Q3 2024 | Oct 30, 2024 | $0.85+23.19% vs estimate | $301.04M-3.38% vs estimate |
|---|
THE ANALYST VIEW
22 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 1 contributors · Median target $320.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$104.57+$1.93 (+1.88%)
Abbott Laboratories’s quoted price sits in the lower half of its reported 52-week range, 20.8% below the high.
$448.76+$4.58 (+1.03%)
Intuitive Surgical, Inc.’s quoted price sits in the lower half of its reported 52-week range, 25.69% below the high.
$97.11+$2.33 (+2.46%)
Medtronic Plc’s quoted price sits in the upper half of its reported 52-week range, 8.67% below the high.
$42.69+$0.26 (+0.61%)
Boston Scientific Corporation’s quoted price sits in the lower half of its reported 52-week range, 59.59% below the high.
$94.44+$2.66 (+2.9%)
Edwards Lifesciences Corporation’s quoted price sits in the upper half of its reported 52-week range, 1.92% below the high.
¥2,388+¥19 (+0.8%)
Terumo Corporation’s quoted price sits in the upper half of its reported 52-week range, 11.19% below the high.
$93.39+$1.18 (+1.28%)
Merit Medical Systems, Inc.’s quoted price sits in the upper half of its reported 52-week range, 6.66% below the high.
$85.27+$2.40 (+2.9%)
LeMaitre Vascular, Inc.’s quoted price sits in the lower half of its reported 52-week range, 27.74% below the high.
